Publications by authors named "Marina Milutinovic"
Article Synopsis
- - Secukinumab, an anti-IL-17A monoclonal antibody, shows significant improvement in psoriasis by 12 weeks, but its long-term molecular effects on inflammation were previously unclear.
- - A 52-week study revealed that patients treated with secukinumab continued to show histological and transcriptomic improvements in psoriatic lesions, with 14 out of 24 patients achieving significant clinical response (≥ 75% improvement).
- - Analysis of skin biopsies indicated that while some genomic profiles of responders improved, they only partially overlapped at different time points; distinct transcript subsets were identified that showed unique expression patterns, suggesting mechanisms driving disease resolution.
Article Synopsis
- Secukinumab has been found effective for moderate-to-severe psoriasis, and examining relapse rates after stopping treatment can help understand long-term remission.
- A clinical trial involving patients who responded well to a year of secukinumab treatment revealed varying relapse rates; 20.8% of those receiving 300 mg remained relapse-free after one year, while only 14% on 150 mg did.
- Factors like shorter disease duration and lower initial severity were linked to better chances of staying relapse-free after stopping secukinumab.
The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis.
J Am Acad Dermatol
September 2020
Background: An Investigator Global Assessment (IGA) is recommended by health agencies for drug registration in atopic dermatitis (AD). Current IGA scales lack standardization.
Objectives: To develop an IGA scale, training module, and clinical certification examination for use in AD trials; establish content validity; and assess reliability.
Background: Plaque psoriasis affecting palms and soles is disabling and often resistant to treatment.
Objective: Evaluate the efficacy and safety of secukinumab, an anti-interleukin 17A antibody, in subjects with palmoplantar psoriasis.
Methods: In this double-blinded, randomized controlled trial, 205 subjects were randomized 1:1:1 to secukinumab 300 mg, 150 mg, or placebo.
Background: Secukinumab demonstrated superior efficacy to ustekinumab at week 4 and week 16 of the CLEAR study, with comparable safety, in subjects with moderate-to-severe plaque psoriasis.
Objective: To compare the efficacy and safety of secukinumab and ustekinumab use over 52 weeks.
Methods: Analysis of 52-week data from CLEAR, a randomized, double-blind, phase 3b study.
Background: Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, has shown superior efficacy to etanercept with similar safety in moderate to severe plaque psoriasis (FIXTURE study).
Objective: We sought to directly compare efficacy and safety of secukinumab versus ustekinumab.
Methods: In this 52-week, double-blind study (NCT02074982), 676 subjects were randomized 1:1 to subcutaneous injection of secukinumab 300 mg or ustekinumab per label.